![David Sandoval](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Sandoval
Compliance Officer bij
MILESTONE PHARMACEUTICALS INC.
Vermogen: 77 705 $ op 31-05-2026
Profiel
David Sandoval currently serves as Chief Compliance Officer & General Counsel at Milestone Pharmaceuticals, Inc. since 2026.
Memberships include the New York State Bar Association and the New Jersey State Bar Association.
Former roles include Senior VP-Legal & Deputy General Counsel at MaxCyte, Inc. from 2023 to 2024, Chief Legal & Compliance Officer at Leadiant Biosciences, Inc. from 2010 to 2023, and Assistant General Counsel at Enzon Pharmaceuticals, Inc. from 2007 to 2010.
Education includes graduate studies at New York University School of Law and undergraduate studies at Cornell University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
MAXCYTE, INC. 0,06% | 18-03-2025 | 64.219 ( 0,06% ) | 77 705 $ | 31-05-2026 |
Actieve functies van David Sandoval
| Bedrijven | Functie | Begin |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Compliance Officer | 10-02-2026 |
New York State Bar Association
 New York State Bar Association Miscellaneous Commercial ServicesCommercial Services Operates as a bar association | Corporate Officer/Principal | - |
New Jersey State Bar Association
 New Jersey State Bar Association Miscellaneous Commercial ServicesCommercial Services Operates as a bar association | Corporate Officer/Principal | - |
Eerdere bekende functies van David Sandoval
| Bedrijven | Functie | Einde |
|---|---|---|
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Compliance Officer | 01-11-2023 |
Enzon Pharmaceuticals, Inc.
 Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Corporate Officer/Principal | 01-01-2010 |
| MAXCYTE, INC. | Algemeen Adviseur | - |
Opleiding van David Sandoval
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
95
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Enzon Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Health Technology |
MaxCyte, Inc.
 MaxCyte, Inc. BiotechnologyHealth Technology Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products | Health Technology |
Milestone Pharmaceuticals, Inc.
 Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Health Technology |
New York State Bar Association
New York State Bar Association Miscellaneous Commercial ServicesCommercial Services Operates as a bar association | Commercial Services |
New Jersey State Bar Association
New Jersey State Bar Association Miscellaneous Commercial ServicesCommercial Services Operates as a bar association | Commercial Services |
New York University School of Law
 New York University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kies MarketScreener 
